CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound
Authors:
- 14 August 2000
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (16) , 1803-1806
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityProceedings of the National Academy of Sciences, 1999
- MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein BJournal of Clinical Investigation, 1999
- Opportunities for novel therapeutic agents acting at chemokine receptorsDrug Discovery Today, 1999
- Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosisNature, 1998
- An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse ModelJournal of Experimental Medicine, 1997
- Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory diseaseMolecular Medicine Today, 1996
- Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.Proceedings of the National Academy of Sciences, 1994